Experts

渋谷 健司/Kenji Shibuya

Kenji Shibuya

  • RESEARCH DIRECTOR

Director, Soma COVID Vaccination Medical Center

Areas of Expertise

  • Global health
  • epidemiology
  • statistics
  • health economics
  • health policy

Research Program

Developing Sustainable and Resilient Health, Nursing, and Long-Term Care Systems in the Post-COVID Era

Establishing Health System Resilience to Tackle the Health Security Crisis

Bio

Dr. Kenji Shibuya is Director of the Soma COVID Vaccination Medical Center in the city of Soma, Fukushima. He was previously Professor and Director of the Institute for Population Health at King’s College London. Before joining King’s, he was Professor and Chair of the Department of Global Health Policy at the University of Tokyo and Coordinator at the World Health Organization (WHO). Dr. Shibuya has been an advisor to both central and local governments, and most recently he was Senior Advisor to the WHO director-general and a member of the Scientific Advisory Committee of the Coalition for Epidemic Preparedness Innovations (CEPI), a pandemic vaccine fund, investing in COVID-19 vaccines. He spearheaded the future strategic directions of the Japanese global health policy agenda at the Hokkaido Toyako G8 Summit in 2008 on health system strengthening and Ise-Shima G7 Summit in 2016 on global health security. He obtained his MD at the University of Tokyo and earned a doctorate of public health in international health economics at Harvard University.


Select Publications

Shimizu K, Sridhar D, Taniguchi K, Shibuya K. “Reconsider this summer’s Olympic and Paralympic games.” BMJ. 2021 Apr 14;373:n962.
Shimizu K, Tokuda Y, Shibuya K. “Japan should aim to eliminate covid -19.” BMJ. 2021; 372: n294.
NCD Risk Factor Collaboration (NCD-RisC). “Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: A pooled analysis of 2181 population-based studies with 65 million participants.” The Lancet. 2020; 396(10261): 1511-1524.
Hen E, Jin Tan MM, Turk E, Sridhar D, Leung GM, Shibuya K, et al. “Lessons learnt from easing COVID-19 restrictions: an analysis of countries and regions in Asia Pacific and Europe.” The Lancet. 2020; 396: 1525-1534.
Legido-Quigley H, Asgari N, Teo YY, Leung GM, Oshitani H, Fukuda K, Cook AR, Hsu LY, Shibuya K, et al. “Are high-performing health systems resilient against the COVID-19 epidemic?” The Lancet. 2020; 395: 848-850.
NCD Risk Factor Collaboration (NCD-RisC). “Repositioning of the global epicentre of non-optimal cholesterol.” Nature. 2020; 582(7810): 73-77.
Nomura S, Yoneoka D, Tanaka S, Makuuchi R, Sakamoto H, Ishizuka A, Nakamura H, Kubota A, Shibuya K. “Limited alignment of publicly competitive disease funding with disease burden in Japan.” PLoS ONE. 2020; 15(2).
Sakamoto H, Ezoe S, Hara K, Hinoshita E, Sekitani Y, Abe K, Inada H, Kato T, Komada K, Miyakawa M, Yamaya H, Yamamoto N, Abe SK, Shibuya K. “The G7 presidency and universal health coverage, Japan’s contribution.” Bulletin of the World Health Organization. 2018; 96(5): 355-9.
Han SM, Rahman MM, Rahman MS, Swe KT, Palmer M, Sakamoto H, Nomura S, Shibuya K. “Progress towards universal health coverage in Myanmar: a national and subnational assessment.” The Lancet Global Health. 2018; 6(9): e989-e97.
Rahman MS, Rahman MM, Gilmour S, Swe KT, Krull Abe S, Shibuya K. “Trends in, and projections of, indicators of universal health coverage in Bangladesh, 1995–2030: a Bayesian analysis of population-based household data.” The Lancet Global Health. 2018; 6(1): e84-e94.
Rahman MM, Karan A, Rahman MS, Parsons A, Abe SK, Bilano V, Awan R, Gilmour S, Shibuya K. “Progress toward universal health coverage: A comparative analysis in 5 South Asian countries.” JAMA Internal Medicine. 2017; 177(9): 1297-305.
GBD 2015 SDG Collaborators. “Measuring the health-related Sustainable Development Goals in 188 countries: A baseline analysis from the Global Burden of Disease Study 2015.” The Lancet. 2016; 388(10053): 1813-1850.
Nomura S, Sakamoto H, Glenn S, Tsugawa Y, Abe SK, Rahman MM, Brown JC, Ezoe S, Fitzmaurice C, Inokuchi T, Kassebaum NJ, Kawakami N, Kita Y, Kondo N, Lim SS, Maruyama S, Miyata H, Mooney MD, Naghavi M, Onoda T, Ota E, Otake Y, Roth GA, Saito E, Tabuchi T, Takasaki Y, Tanimura T, Uechi M, Vos T, Wang H, Inoue M, Murray CJL, Shibuya K. “Population health and regional variations of disease burden in Japan, 1990–2015: A systematic subnational analysis for the Global Burden of Disease Study 2015.” The Lancet. 2017; 390(10101): 1521-38.
NCD Risk Factor Collaboration (NCD-RisC). “Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19.2 million participants.” The Lancet. 2016; 387(10026): 1377-96.
Shibuya K, et al. “Protecting human security: Proposals for the G7 Ise-Shima Summit in Japan.” The Lancet. 2016; 387(10033): 2155-62.8).
Reich MR, Shibuya K. “The future of Japan’s health system: Sustaining good health with equity at low cost.” New England Journal of Medicine. 2015; 373(19): 1793-7.
GBD 2013 Mortality and Causes of Death Collaborators. “Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: A systematic analysis for the Global Burden of Disease Study 2013.” The Lancet. 2015; 385(9963): 117-71.
Bilano V, Gilmour S, Moffiet T, D’Espaignet ET, Stevens GA, Commar A, Tuyl F, Hudson I, Shibuya K. “Global trends and projections for tobacco use, 1990-2025: An analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control.” The Lancet. 2015; 385(9972): 966-76.
Li J, Gilmour S, Zhang H, Koyanagi A, Shibuya K. “The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programs.” AIDS. 2012; 26(16): 2069-78.
Shibuya K, Hashimoto H, Ikegami N, Nishi A, Tanimoto T, Miyata H, Takemi K, Reich MR. “Future of Japan’s system of good health at low cost with equity: Beyond universal coverage.” The Lancet. 2011; 378(9798): 1265-73.